The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Dolobid     5-(2,4-difluorophenyl)-2- hydroxy-benzoic acid

Synonyms: Dolobis, Dolocid, diflunisal, Nu-Diflunisal, Apo-Diflunisal, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dolobid


Psychiatry related information on Dolobid


High impact information on Dolobid


Chemical compound and disease context of Dolobid


Biological context of Dolobid


Anatomical context of Dolobid

  • In none of 28 patients studied could any trace of diflunisal be observed in cerebrospinal fluid, even though the sensitivity of the assay allowed detection of concentrations as low as 0.01 mg/L [18].
  • The AUC for diflunisal in synovial fluid collected from 66 patients was about 70% of that for plasma [18].
  • Glucuronidation of diflunisal by rat liver microsomes. Effect of microsomal beta-glucuronidase activity [19].
  • Ionophoretic and inhibitory action of the analgesic, diflunisal, on sarcoplasmic reticulum [20].
  • NSAIDs comprised an interesting pharmacological class in that some compounds, notably diflunisal, co-clustered with peroxisome proliferators whereas several others co-clustered with macrophage activators, possibly due to endotoxin exposure secondary to their adverse effects on the gastrointestinal system [21].

Associations of Dolobid with other chemical compounds


Gene context of Dolobid


Analytical, diagnostic and therapeutic context of Dolobid

  • Diflunisal plus codeine was better than placebo from 1 1/2 to 8 hours (p less than 0.01), better than codeine from 1 1/2 to 6 hours (p less than 0.05), and better than diflunisal alone from 1/2 to 1 1/2 hours (p less than 0.05) for most measures of analgesia [4].
  • In a double-blind crossover study in 2 subjects, diflunisal, 250 mg twice daily again did not significantly affect fecal blood loss during a 4-day treatment period, and there also was no significant effth diflunisal during two additional treatment days [30].
  • A double-blind study of diflunisal and codeine compared with codeine or diflunisal alone in postoperative pain [4].
  • Binding studies with plasma from uremic patients during hemodialysis revealed that free diflunisal rose from 0.46 +/- 0.04% at the start to 0.61 +/- 0.06% at the end of dialysis [16].
  • The activity of ALP is measured with the substrate diflunisal phosphate; the released diflunisal forms highly fluorescent complexes with Tb(3+)-EDTA that are quantified with microsecond time-resolved fluorometry [31].


  1. Necrotising fasciitis after diflunisal for minor injury. Krige, J.E., Spence, R.A., Potter, P.C., Terblanche, J. Lancet (1985) [Pubmed]
  2. Diflunisal-associated thrombocytopenia in a patient with rheumatoid arthritis. Bobrove, A.M. Arthritis Rheum. (1988) [Pubmed]
  3. Diflunisal disposition and hypouricemic response in osteoarthritis. Meffin, P.J., Brooks, P.M., Bertouch, J., Veenendaal, J.R., Harrington, B.J. Clin. Pharmacol. Ther. (1983) [Pubmed]
  4. A double-blind study of diflunisal and codeine compared with codeine or diflunisal alone in postoperative pain. Jain, A., McMahon, F.G., Ryan, J.R., Smith, G., Berman, R. Clin. Pharmacol. Ther. (1988) [Pubmed]
  5. Diflunisal in idiopathic Parkinson's disease. Anderson, C.B., Larson, E.J. Neurology (1984) [Pubmed]
  6. Effects of diflunisal on cutaneous sensory and pain thresholds. Dragani, L., Giamberardino, M.A., Obletter, G., Vecchiet, L. Clinical therapeutics. (1988) [Pubmed]
  7. Effect of diflunisal on in vitro platelet aggregation. Mikhailidis, D.P., Freedman, D.B., Dandona, P. Lancet (1980) [Pubmed]
  8. Diflunisal, aspirin, and gastric mucosa. Petrillo, M., Caruso, I., Fumagalli, M., Montrone, F., Lazzaroni, M., Porro, G.B. Lancet (1979) [Pubmed]
  9. Rational design of diflunisal analogues with reduced affinity for human serum albumin. Mao, H., Hajduk, P.J., Craig, R., Bell, R., Borre, T., Fesik, S.W. J. Am. Chem. Soc. (2001) [Pubmed]
  10. Interactions between oleic acid and drug competitors influence specific binding of thyroxine in serum. Lim, C.F., Curtis, A.J., Barlow, J.W., Topliss, D.J., Stockigt, J.R. J. Clin. Endocrinol. Metab. (1991) [Pubmed]
  11. Comparative acute effects of diflunisal and indomethacin on renal function in patients with cirrhosis and ascites. Antillon, M., Cominelli, F., Reynolds, T.B., Zipser, R.D. Am. J. Gastroenterol. (1989) [Pubmed]
  12. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Miller, S.R., Sekijima, Y., Kelly, J.W. Lab. Invest. (2004) [Pubmed]
  13. Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain. Berry, H., Bloom, B., Hamilton, E.B., Swinson, D.R. Ann. Rheum. Dis. (1982) [Pubmed]
  14. Treatment of mild to moderate pain of acute soft tissue injury: diflunisal vs acetaminophen with codeine. Muncie, H.L., King, D.E., DeForge, B. The Journal of family practice. (1986) [Pubmed]
  15. Efficacy of diflunisal versus naproxen in osteoarthritis of the knee: an open study. Deal, C.L., Moskowitz, R.W. Clinical therapeutics. (1986) [Pubmed]
  16. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Verbeeck, R.K., De Schepper, P.J. Clin. Pharmacol. Ther. (1980) [Pubmed]
  17. Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states. Tobert, J.A., DeSchepper, P., Tjandramaga, T.B., Mullie, A., Buntinx, A.P., Meisinger, M.A., Huber, P.B., Hall, T.L., Yeh, K.C. Clin. Pharmacol. Ther. (1981) [Pubmed]
  18. Pharmacokinetics of diflunisal in patients. Nuernberg, B., Koehler, G., Brune, K. Clinical pharmacokinetics. (1991) [Pubmed]
  19. Glucuronidation of diflunisal by rat liver microsomes. Effect of microsomal beta-glucuronidase activity. Brunelle, F.M., Verbeeck, R.K. Biochem. Pharmacol. (1993) [Pubmed]
  20. Ionophoretic and inhibitory action of the analgesic, diflunisal, on sarcoplasmic reticulum. Holguín, J.A. Biochem. Pharmacol. (1988) [Pubmed]
  21. Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. McMillian, M., Nie, A.Y., Parker, J.B., Leone, A., Kemmerer, M., Bryant, S., Herlich, J., Yieh, L., Bittner, A., Liu, X., Wan, J., Johnson, M.D. Biochem. Pharmacol. (2004) [Pubmed]
  22. Standards of laboratory practice: analgesic drug monitoring. National Academy of Clinical Biochemistry. White, S., Wong, S.H. Clin. Chem. (1998) [Pubmed]
  23. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Hwang, S.B., Li, C.L., Lam, M.H., Shen, T.Y. Lab. Invest. (1985) [Pubmed]
  24. Studies on the reactivity of acyl glucuronides--VI. Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Williams, A.M., Dickinson, R.G. Biochem. Pharmacol. (1994) [Pubmed]
  25. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Bailey, M.J., Dickinson, R.G. Chem. Res. Toxicol. (1996) [Pubmed]
  26. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Mano, Y., Usui, T., Kamimura, H. Eur. J. Clin. Pharmacol. (2007) [Pubmed]
  27. Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. Munro, S.L., Lim, C.F., Hall, J.G., Barlow, J.W., Craik, D.J., Topliss, D.J., Stockigt, J.R. J. Clin. Endocrinol. Metab. (1989) [Pubmed]
  28. Studies on the reactivity of acyl glucuronides--II. Interaction of diflunisal acyl glucuronide and its isomers with human serum albumin in vitro. Dickinson, R.G., King, A.R. Biochem. Pharmacol. (1991) [Pubmed]
  29. Effect of cyclodextrins on protein binding of drugs: the diflunisal/hydroxypropyl-beta-cyclodextrin model case. Sideris, E.E., Koupparis, M.A., Macheras, P.E. Pharm. Res. (1994) [Pubmed]
  30. Gastrointestinal blood loss after diflunisal and after aspirin: effect of ethanol. DeSchepper, P.J., Tjandramaga, T.B., De Roo, M., Verhaest, L., Daurio, C., Steelman, S.L., Tempero, K.F. Clin. Pharmacol. Ther. (1978) [Pubmed]
  31. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Yu, H., Diamandis, E.P. Clin. Chem. (1993) [Pubmed]
WikiGenes - Universities